Zelira Therapeutics Limited

ASX:ZLD 株式レポート

時価総額:AU$8.1m

Zelira Therapeutics 過去の業績

過去 基準チェック /06

Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.

主要情報

-41.7%

収益成長率

-20.6%

EPS成長率

Pharmaceuticals 業界の成長31.2%
収益成長率-3.5%
株主資本利益率n/a
ネット・マージン-38,513.0%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

収支内訳

Zelira Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

ASX:ZLD 収益、費用、利益 ( )AUD Millions
日付収益収益G+A経費研究開発費
30 Jun 240-3723
31 Mar 240-3632
31 Dec 230-3641
30 Sep 230-2141
30 Jun 230-651
31 Mar 231-882
31 Dec 221-10102
30 Sep 221-11112
30 Jun 222-12121
31 Mar 221-11101
31 Dec 211-1081
30 Sep 211-982
30 Jun 211-972
31 Mar 210-863
31 Dec 200-854
30 Sep 200-854
30 Jun 200-744
31 Mar 200-633
31 Dec 191-433
30 Sep 191-423
30 Jun 191-422
31 Mar 191-312
31 Dec 180-312
30 Sep 180-312
30 Jun 180-212
31 Mar 180-212
31 Dec 170-211
30 Sep 170-411
30 Jun 170-621
31 Dec 160-520
30 Jun 160000

質の高い収益: ZLD is currently unprofitable.

利益率の向上: ZLD is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

成長の加速: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


株主資本利益率

高いROE: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘